Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy
Aim. To estimate the impact of recipient IL28B genotypes on rapid (RVR) and early virologic responses (EVR) pattern in liver transplant recipients undergoing antiviral treatment (AVT).Material and methods. Blood samples were screened for single nucleotide polymorphisms (SNP) near the IL28B genes (rs...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2011-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1475 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860179428442112 |
|---|---|
| author | V. E. Syutkin V. P. Chulanov I. V. Karandashova V. A. Dolgin A. O. Chugunov |
| author_facet | V. E. Syutkin V. P. Chulanov I. V. Karandashova V. A. Dolgin A. O. Chugunov |
| author_sort | V. E. Syutkin |
| collection | DOAJ |
| description | Aim. To estimate the impact of recipient IL28B genotypes on rapid (RVR) and early virologic responses (EVR) pattern in liver transplant recipients undergoing antiviral treatment (AVT).Material and methods. Blood samples were screened for single nucleotide polymorphisms (SNP) near the IL28B genes (rs8099917 T ≥G and rs12979860 C>T) by kit «AmpliSens® Genoscreen-IL28B-FL» (CRIE) in 24 HCV-infected recipients. All the patients underwent pegylated interferon-alfa with (n=21) or without (n=3) ribavirin at least for 12 weeks.Results. Five recipients achieved RVR (one has HCV genotype 1 and 4 patients – HCV genotype 2 or 3) and other 10 – complete EVR. In 6 cases slow virologic response (aviremia between 12 and 24 weeks of treatment, SlVR) occurred. Three patients remained non-responders. G-allele (rs80999917) was present in 3 (20%) out of 15 pts. with complete EVR and in 5 out of 6patients with SlVR (p=0.014). Genotype C/C (rs12979860) was present in 6 (40%) patients with complete EVR and in none of slow-responders (one-sided p=0.041).The groups of recipients with and without complete EVR were comparable with sex, age, pre-treatment viral load, immunosuppression (cyclosporine vs. tacrolimus), weight and body mass index, and mean ribavirin dose. The only pre-treatment factors which have impact on complete EVR were genotype (1 vs. non-1) and IL28B polymorphisms.Conclusion. The SNP in IL28B region may predict slow response to AT in post-LTx setting and should be considered when AT duration is planning. |
| format | Article |
| id | doaj-art-236c8992d77241c18eb397e68d25636a |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2011-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-236c8992d77241c18eb397e68d25636a2025-02-10T16:14:31ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732011-12-012164955999Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapyV. E. SyutkinV. P. ChulanovI. V. KarandashovaV. A. DolginA. O. ChugunovAim. To estimate the impact of recipient IL28B genotypes on rapid (RVR) and early virologic responses (EVR) pattern in liver transplant recipients undergoing antiviral treatment (AVT).Material and methods. Blood samples were screened for single nucleotide polymorphisms (SNP) near the IL28B genes (rs8099917 T ≥G and rs12979860 C>T) by kit «AmpliSens® Genoscreen-IL28B-FL» (CRIE) in 24 HCV-infected recipients. All the patients underwent pegylated interferon-alfa with (n=21) or without (n=3) ribavirin at least for 12 weeks.Results. Five recipients achieved RVR (one has HCV genotype 1 and 4 patients – HCV genotype 2 or 3) and other 10 – complete EVR. In 6 cases slow virologic response (aviremia between 12 and 24 weeks of treatment, SlVR) occurred. Three patients remained non-responders. G-allele (rs80999917) was present in 3 (20%) out of 15 pts. with complete EVR and in 5 out of 6patients with SlVR (p=0.014). Genotype C/C (rs12979860) was present in 6 (40%) patients with complete EVR and in none of slow-responders (one-sided p=0.041).The groups of recipients with and without complete EVR were comparable with sex, age, pre-treatment viral load, immunosuppression (cyclosporine vs. tacrolimus), weight and body mass index, and mean ribavirin dose. The only pre-treatment factors which have impact on complete EVR were genotype (1 vs. non-1) and IL28B polymorphisms.Conclusion. The SNP in IL28B region may predict slow response to AT in post-LTx setting and should be considered when AT duration is planning.https://www.gastro-j.ru/jour/article/view/1475interleukin 28вpegilated interferonhepatitis c virusearly viral kinetics |
| spellingShingle | V. E. Syutkin V. P. Chulanov I. V. Karandashova V. A. Dolgin A. O. Chugunov Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy Российский журнал гастроэнтерологии, гепатологии, колопроктологии interleukin 28в pegilated interferon hepatitis c virus early viral kinetics |
| title | Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy |
| title_full | Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy |
| title_fullStr | Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy |
| title_full_unstemmed | Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy |
| title_short | Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy |
| title_sort | interleukin 28b polymorphism impact on early hcv kinetics in hcv infected liver transplant recipients undergoing antiviral therapy |
| topic | interleukin 28в pegilated interferon hepatitis c virus early viral kinetics |
| url | https://www.gastro-j.ru/jour/article/view/1475 |
| work_keys_str_mv | AT vesyutkin interleukin28bpolymorphismimpactonearlyhcvkineticsinhcvinfectedlivertransplantrecipientsundergoingantiviraltherapy AT vpchulanov interleukin28bpolymorphismimpactonearlyhcvkineticsinhcvinfectedlivertransplantrecipientsundergoingantiviraltherapy AT ivkarandashova interleukin28bpolymorphismimpactonearlyhcvkineticsinhcvinfectedlivertransplantrecipientsundergoingantiviraltherapy AT vadolgin interleukin28bpolymorphismimpactonearlyhcvkineticsinhcvinfectedlivertransplantrecipientsundergoingantiviraltherapy AT aochugunov interleukin28bpolymorphismimpactonearlyhcvkineticsinhcvinfectedlivertransplantrecipientsundergoingantiviraltherapy |